Global Yellow Fever Vaccine Market Size By Type (Powder, Liquid), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Yellow Fever Vaccine Market was valued at USD 510 million in 2023 and is projected to reach USD 915 million by 2031, expanding at a CAGR of 7.3% during the forecast period (2023–2031). The market is driven by rising global initiatives for immunization, increased international travel to endemic regions, and growing awareness of mosquito-borne diseases. The growing threat of yellow fever outbreaks, especially in Africa and South America, along with increased support from health organizations such as the WHO and GAVI, is expected to sustain long-term demand for effective vaccines.

Drivers:

1. Intensified Immunization Campaigns:

Global initiatives led by WHO and national governments to eliminate yellow fever epidemics are fueling market growth. The Eliminate Yellow fever Epidemics (EYE) strategy has significantly boosted vaccine procurement and distribution across vulnerable regions.

2. Increased International Travel:

With the easing of pandemic-era travel restrictions, international tourism and travel to yellow fever-endemic regions are rising. Many countries mandate vaccination proof for entry, thereby bolstering demand for the vaccine.

3. Advancements in Vaccine Manufacturing:

Improvements in cold-chain logistics and the development of fractional dose strategies have enhanced vaccine accessibility, especially in resource-constrained areas, allowing broader coverage during outbreak responses.

Restraints:

1. Limited Manufacturing Capacity:

Despite rising demand, global yellow fever vaccine supply is constrained by the limited number of manufacturers and complex production processes, leading to periodic shortages during outbreaks.

2. Stringent Regulatory Requirements:

The regulatory landscape for vaccine development and approval remains highly rigorous, often prolonging time-to-market for new or improved formulations and affecting supply during emergencies.

Opportunity:

1. Expansion in Non-Endemic Countries:

Rising concerns about global disease outbreaks are pushing non-endemic countries to stockpile yellow fever vaccines. These proactive public health measures are opening new market avenues.

2. Integration with Routine Immunization Programs:

Introducing yellow fever vaccines into broader pediatric and adult immunization schedules, particularly in Africa and Latin America, represents a major growth opportunity for long-term disease control.

Market by System Type Insights:

By vaccine type, Live Attenuated Vaccines dominate the market and accounted for the largest share in 2023 due to their proven efficacy and long-term protection with a single dose. However, Next-generation Recombinant Vaccines are gaining attention and are expected to witness the fastest growth, as they offer potentially fewer side effects and improved safety profiles for immune-compromised populations.

Market by End-use Insights:

The Public Health Sector segment held the majority share in 2023, driven by mass immunization programs initiated by government and international agencies. The Private Clinics and Travel Clinics segment is also expanding steadily, especially in developed regions where travelers are routinely vaccinated before visiting endemic areas.

Market by Regional Insights:

Africa emerged as the largest regional market in 2023, owing to frequent outbreaks, high endemicity, and strong support from international health organizations. South America followed, with countries like Brazil investing heavily in vaccination campaigns. Meanwhile, Asia-Pacific is projected to experience the fastest growth during the forecast period due to increased travel and urban mosquito proliferation.

Competitive Scenario:

Key players in the Global Yellow Fever Vaccine Market include Sanofi Pasteur, Bio-Manguinhos/Fiocruz, Chumakov Federal Scientific Center, Institut Pasteur de Dakar, and Bharat Biotech. These companies are focused on enhancing production capacity, expanding geographic reach, and securing WHO prequalification to supply international public health programs.

Recent Developments:

In 2023, Sanofi Pasteur announced a capacity expansion at its French vaccine facility to increase yellow fever vaccine output.

In 2024, Bio-Manguinhos signed an agreement with PAHO to supply millions of doses across Latin America.

In 2025, Bharat Biotech began Phase II trials for a recombinant yellow fever vaccine candidate targeting travelers and immunocompromised individuals.

Scope of Work – Global Yellow Fever Vaccine Market

Key Market Developments:

2023: WHO initiated the rollout of fractional dosing strategies in high-risk African countries.

2024: Chumakov Center received WHO prequalification for export of yellow fever vaccine to Middle Eastern nations.

2025: Sanofi Pasteur launched an awareness campaign in partnership with global airlines to improve traveler vaccination rates.

FAQs:

1) What is the current market size of the Global Yellow Fever Vaccine Market?

The market was valued at USD 510 million in 2023.

2) What is the major growth driver of the Global Yellow Fever Vaccine Market?

The major driver is intensified global immunization campaigns, especially in endemic regions.

3) Which is the largest region during the forecast period in the Global Yellow Fever Vaccine Market?

Africa is expected to remain the largest region due to frequent outbreaks and high immunization needs.

4) Which segment accounted for the largest market share in the Global Yellow Fever Vaccine Market?

The Live Attenuated Vaccine segment held the largest market share in 2023.

5) Who are the key market players in the Global Yellow Fever Vaccine Market?

Key players include Sanofi Pasteur, Bio-Manguinhos/Fiocruz, Institut Pasteur de Dakar, Chumakov Center, and Bharat Biotech.